Novo Nordisk A/S (NYSE:NVO) Shares Cross Above 50-Day Moving Average - Here's Why

Key Points

• Novo Nordisk shares rose about 5% and moved above their 50-day moving average, trading as high as $43.24 versus the average of $40.84.
• The company beat third-quarter sales and earnings expectations, with obesity-drug sales up 22%, and raised its 2026 outlook. Stronger-than-expected Wegovy pill sales and plans to expand its availability supported the outlook.
• Risks remain: Novo did not provide 2027 guidance, and analysts flagged pricing pressure and weakness in diabetes products. MarketBeat’s analyst consensus remains “Hold.”

Novo Nordisk A/S (NYSE:NVO - Get Free Report) shares crossed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $40.84 and traded as high as $43.24. Novo Nordisk A/S shares last traded at $42.2070, with a volume of 25,980,432 shares traded.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo beat analysts’ third-quarter sales and earnings estimates, with obesity-drug sales up 22%. It raised its full-year 2026 sales and operating-profit outlook, citing demand for its GLP-1 medicines. Reuters: Novo Nordisk Q3 profit beats forecast; raises 2026 guidance
• Positive Sentiment: Wegovy pill sales exceeded expectations, helping bolster the outlook and Novo’s position in the weight-loss market. The company added 1.3 million patients in Q3 and plans to bring the pill to more than 20 markets by mid-2027. BioPharma Dive: Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
• Positive Sentiment: Novo and Abbott expanded their collaboration on a diabetes drug in Asia, potentially supporting broader reach in the region. MarketScreener: Abbott and Novo Nordisk expand collaboration on diabetes drug in Asia
• Neutral Sentiment: CEO Mike Doustdar declined to provide 2027 guidance. He cited factors that could support or weigh on next year’s sales, leaving investors without a firm view of growth beyond 2026. The Motley Fool: Novo Nordisk Stock Jumped After Earnings — But Its CEO Won't Give 2027 Guidance
• Negative Sentiment: Despite the outlook increase, Jefferies did not upgrade its rating, and Deutsche Bank reiterated a sell rating while raising its price target. Pricing pressure and weakness in diabetes products remain risks; impairment charges also weighed on reported operating profit. MarketScreener: Deutsche Bank raises price target, reiterates sell

Analysts Set New Price Targets

A number of research firms have recently weighed in on NVO. DZ Bank reiterated a "neutral" rating on shares of Novo Nordisk A/S in a research report on Thursday, August 6th. Zacks Research raised Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 11th. Barclays restated a "neutral" rating on shares of Novo Nordisk A/S in a research note on Monday, September 7th. Jefferies Financial Group restated a "neutral" rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "sell" rating on shares of Novo Nordisk A/S in a report on Tuesday, September 29th. Five investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $59.44.

Novo Nordisk A/S Trading Up 5.0%

The firm's fifty day simple moving average is $40.84 and its 200 day simple moving average is $44.07. The stock has a market capitalization of $188.45 billion, a P/E ratio of 10.32, a price-to-earnings-growth ratio of 1.36 and a beta of 0.70. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.66 and a current ratio of 0.87.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The company had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership acquired a new position in Novo Nordisk A/S in the first quarter valued at $287,660,000. State Street Corp grew its holdings in Novo Nordisk A/S by 0.6% during the 2nd quarter. State Street Corp now owns 5,869,834 shares of the company's stock worth $284,565,000 after acquiring an additional 32,641 shares during the period. Envestnet Asset Management Inc. raised its position in shares of Novo Nordisk A/S by 1.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company's stock worth $193,250,000 after acquiring an additional 71,684 shares in the last quarter. Royal Bank of Canada raised its position in shares of Novo Nordisk A/S by 3.2% in the 1st quarter. Royal Bank of Canada now owns 4,527,779 shares of the company's stock worth $166,396,000 after acquiring an additional 141,376 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Novo Nordisk A/S by 6.7% in the 1st quarter. Renaissance Technologies LLC now owns 3,397,121 shares of the company's stock valued at $124,844,000 after purchasing an additional 213,443 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.